Litigation Details for CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA (D. Del. 2019)

CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA (D. Del. 2019)

Docket		Date Filed	2019-05-23
Court	District Court, D. Delaware	Date Terminated	2021-06-10
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,410,077; 9,200,088; 9,493,582
Link to Docket	External link to docket

Details for CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2019-05-23	1	Complaint	and lawfully issued United States Patent No. 9,200,088 (“the ’088 patent”), entitled “Sulfoalkyl Ether … COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 9,200,088 26. CyDex realleges and incorporates…and interest in the ’088 patent and the ’582 patent (collectively, “the patents-in-suit”). … 1. This is an action for patent infringement under the patent laws of the United States arising…. This is an action for patent infringement arising under the Patent Laws of the United States,	External link to document
2020-11-01	122	Opinion - Memorandum Opinion	infringement of an additional patent, U.S. Patent No. 8,410,077 (the 077 patent”) (D.I. 41 Ex. C). (See generally…of U.S. Patent Nos. 9,200,088 (the “088 patent”) (D.I. 1 Ex. A); and 9,493,5 82 (the “582 patent”) (D.I…. “It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent.” fd. at 1321 (internal quotation marks omitted). The patent “specification is….” (582 patent at 6:19-34) The Court’s construction | This term appears in the 088 patent at claims	External link to document